Analysts expect Viridian Therapeutics, Inc.\DE to report revenue of 4.43 M for Q3 26, against a range of 4.17 M to 4.69 M. The most recent reported quarter, Q2 26, came in at 284,000.00, a 441.4% beat against the 52,454.53 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 86,000.00 | 72,000.00 | 72,000.00 | 75,000.00 | 70.57 M | 132,000.00 | 141,000.00 | 284,000.00 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | 90,540.05 | 45,069.09 | 54,347.02 | 53,861.79 | 34,213.90 | 18.20 M | 40,724.22 | 56,742.01 | 4.69 M | 20.15 M | 43.32 M | 73.74 M | 125.12 M | 137.50 M | 62.44 M | 94.60 M | ||||||||||
| Low Estimate | 75,763.03 | 40,972.47 | 50,524.76 | 44,579.29 | 31,824.12 | 16.83 M | 35,987.64 | 48,167.05 | 4.17 M | 17.22 M | 40.65 M | 64.57 M | 110.65 M | 125.91 M | 55.36 M | 77.96 M | ||||||||||
| Consensus Estimate | 83,151.54 | 43,020.78 | 52,435.89 | 49,220.54 | 33,019.01 | 17.52 M | 38,355.93 | 52,454.53 | 4.43 M | 18.69 M | 41.99 M | 69.16 M | 117.88 M | 131.71 M | 58.90 M | 86.28 M |
Analysts expect Viridian Therapeutics, Inc.\DE to report earnings per share of -0.94 for Q3 26, against a range of -1.02 to -0.86. The most recent reported quarter, Q2 26, came in at -1.05, a 6.1% miss against the -0.99 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -1.15 | -0.81 | -0.87 | -1.00 | -0.34 | -1.08 | -0.90 | -1.05 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | -1.07 | -1.04 | -0.97 | -1.01 | -1.02 | -0.99 | -0.95 | -0.93 | -0.86 | -0.81 | -0.77 | -0.55 | -0.50 | -0.70 | -0.29 | -0.07 | ||||||||||
| Low Estimate | -1.17 | -1.16 | -1.05 | -1.11 | -1.14 | -1.07 | -1.07 | -1.05 | -1.02 | -0.97 | -0.83 | -0.63 | -0.54 | -0.78 | -0.33 | -0.09 | ||||||||||
| Consensus Estimate | -1.12 | -1.10 | -1.01 | -1.06 | -1.08 | -1.03 | -1.01 | -0.99 | -0.94 | -0.89 | -0.80 | -0.59 | -0.52 | -0.74 | -0.31 | -0.08 |
Pull Wall Street consensus for Viridian Therapeutics, Inc.\DE (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=VRDN&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "VRDN", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=VRDN&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();